Published in Theranostics on May 08, 2012
Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging (2015) 1.41
Prospective of ⁶⁸Ga-radiopharmaceutical development. Theranostics (2013) 1.32
PET imaging of inflammation biomarkers. Theranostics (2013) 1.04
Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics. Pharmacol Rev (2013) 0.89
Positron emission tomography image-guided drug delivery: current status and future perspectives. Mol Pharm (2014) 0.88
Molecular imaging and radiotherapy: theranostics for personalized patient management. Theranostics (2012) 0.80
Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. Pharmaceuticals (Basel) (2017) 0.75
Carbon fluoroxide nanoparticles as fluorescent labels and sonosensitizers for theranostic applications. Sci Technol Adv Mater (2015) 0.75
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem (1969) 6.06
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol (2008) 4.66
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med (2007) 3.98
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med (1993) 3.45
Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med (2000) 3.26
The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am (2011) 2.95
The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev (2004) 2.88
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol (2011) 2.72
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med (2002) 2.44
Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med (2001) 2.41
[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med (2001) 2.11
Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging (2003) 2.05
Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol (2008) 2.03
Imaging of neuroendocrine tumors. Semin Nucl Med (2006) 2.01
Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet (1989) 1.76
Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging (2007) 1.72
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol (2001) 1.60
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med (1992) 1.54
90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol (2010) 1.49
Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med (1999) 1.46
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging (2003) 1.46
18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res (2010) 1.45
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med (2006) 1.44
Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med (2002) 1.40
Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med (1998) 1.36
Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology (1995) 1.26
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol (2003) 1.25
Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res (1988) 1.24
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm (2007) 1.23
PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci (2004) 1.17
In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med (2002) 1.16
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med (2002) 1.10
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol (2004) 1.08
Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging (2006) 1.05
Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med (2003) 0.99
Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med (2002) 0.94
Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors. Cancer Biother Radiopharm (2008) 0.93
Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors. J Clin Oncol (1998) 0.93
Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging (2003) 0.88
Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med (2000) 0.85
Molecular theranostics: a primer for the imaging professional. AJR Am J Roentgenol (2011) 0.83